Form D · Biotechnology
Oisin Biotechnologies, Inc.
Seattle, WA · CIK 0001801885
Offering snapshot reported Jul 12, 2024 · SEC filing
- Reported sold
- $5.38M Offering amount: $17.9M
- Investors reported
- 36 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 28, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 12, 2024 | Initial | $5,380,000 | No comparison | 36 | SEC filing |
| Aug 6, 2021 | Initial | $475,000 | No comparison | 8 | SEC filing |
| May 28, 2021 | Amendment | $9,531,365 | No comparison | Not reported | SEC filing |
| Jun 23, 2020 | Initial | $2,118,936 | No comparison | 27 | SEC filing |
| Feb 25, 2020 | Initial | $2,974,976 | No comparison | 48 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-518582
Source: Form D, filed Jul 12, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Eric Garcia | Executive |
| David Gobel | Director |
| Stephen Hilbert | Executive |
| Steve Hilbert | Executive |
| Gary Hudson | Director, Executive |
| John Lewis | Executive |
| Danjuma Quarless | Director |
| Matthew Scholz | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
800 5 Th Avenue, Suite 4100
Seattle, WA, 98104
Seattle, WA, 98104